We studied intensity of pain, cumulative morphine consumption, ventilatory and renal function, and haemostasis in patients undergoing video-assisted thoracoscopic surgery and receiving a 2-day i.v. infusion of diclofenac, ketorolac or saline. Plasma concentrations of the two NSAID were also measured. The study was randomized, double-blind and placebo-controlled, with 10 patients in each group. Patients experienced mainly moderate pain. Mean consumption of i.v. morphine during the first day after operation was 57 (SEM 11) mg in the placebo group. Diclofenac and ketorolac were equally effective in reducing total morphine consumption (61% and 52%, respectively). Adverse events were similar and minor. Greater variability in plasma concentrations of ketorolac were detected compared with diclofenac. 1999; 82: 221-7 
Video-assisted thoracic surgery has become popular for procedures such as obtaining biopsies from the lung. 1 Thoracoscopic surgery is less invasive and causes less tissue damage compared with normal thoracotomy and therefore it is assumed that it also causes less postoperative pain. 2 Various methods have been used for the treatment of post-thoracotomy pain, which is often severe. 3 Systemic opioids are used commonly but they are a potential cause of ventilatory depression. Non-steroidal anti-inflammatory drugs (NSAID) have been shown to be effective in the treatment of pain and in reducing opioid consumption after thoracotomy. 4 5 NSAID do not cause respiratory depression but other adverse events may occur. These include increased bleeding time, gastrointestinal symptoms, central nervous system symptoms and depression of renal function.
Diclofenac is the sodium salt of amino-phenylacetic acid. It was developed as an analgesic, but it also has antiinflammatory and antipyretic properties. 6 Diclofenac has been reported to reduce opioid consumption by 60-76% after thoracic surgery. 4 Ketorolac, a pyrrolizine carboxylic acid derivate, structurally related to indomethacin, is used principally for its analgesic activity. Ketorolac reduced opioid consumption by 35-66% after orthopaedic surgery. 7 8 The aim of this study was to assess the amount of postoperative pain experienced after video-assisted thoracoscopic surgery (VATS) using the same pain relief method that has been validated after thoracic surgery. 4 A second objective was to compare i.v. ketorolac with i.v. diclofenac © British Journal of Anaesthesia in terms of efficacy and adverse events. The steady state pharmacokinetics of these two drugs were also studied.
Patients and methods
After obtaining approval from the Institutional Ethics Committee and informed patient consent, we studied 30 patients undergoing elective video-assisted thoracoscopic surgery at the Helsinki University Central Hospital, in a randomized, double-blind, placebo-controlled, parallelgroup study.
ASA I-III adult patients, less than 75 yr of age, were eligible. Patients with cardiac, renal or hepatic failure were excluded, as were those with a history of gastrointestinal bleeding or peptic ulceration, haemorrhagic diathesis and asthma, or allergy to acetosalicylic acid or other nonsteroidal anti-inflammatory analgesics or morphine. Confused patients, those with a preoperative forced expiratory volume in 1 s (FEV 1 ) of less than 60% of the reference value and patients with sleep apnoea were also excluded.
All patients received a standard anaesthesia. Morphine 0.13 mg kg -1 i.m. was given as premedication approximately 1 h before operation. Glycopyrrolate 0.2 mg i.v. was administered just before induction. After precurarization with pancuronium 15 µg kg -1 , general anaesthesia was induced with fentanyl 0.003 mg kg -1 and thiopental. Succinylcholine 1.5 mg kg -1 was given to facilitate endobronchial intubation (Robertshaw or Bronchocath tubes). No more opioids were given during anaesthesia, which was maintained with 1-2.5% enflurane and 60% nitrous oxide in oxygen. During one-lung ventilation the inspired oxygen concentration was increased to 100%. Neuromuscular block was achieved with pancuronium and monitored visually using a peripheral nerve stimulator. Normoventilation was controlled by continuous monitoring of end-tidal carbon dioxide concentration and repeated arterial blood-gas analyses at least every 30 min. At the end of anaesthesia, residual neuromuscular block was antagonized with neostigmine 2 mg and glycopyrrolate 0.4 mg i.v. Pulmonary operations were performed using standardized thoracoscopy, 9 in which three intercostal ports (diameter 5-12 mm) were used for insertion of the thoracoscope and instruments into the pleural cavity.
Patients were allocated randomly using sealed envelopes to receive, in a double-blind manner, diclofenac, ketorolac or placebo infusion, started approximately 1 h before anaesthesia. The infusions were prepared by a recovery room nurse who was not otherwise involved in the study. The diclofenac infusion (1 mg ml -1 in 0.9% NaCl) was started with a bolus dose of 17 ml (ϭ17 mg) in 30 min and continued with a constant rate of 2 ml kg -1 /24 h for 48 h. The maximum daily dose was 150 mg. The ketorolac infusion (0.6 mg ml -1 in 0.9% NaCl) was started with a bolus dose of 17 ml (ϭ10 mg) in 30 min and continued with a constant rate of 2 ml kg -1 /24 h for 48 h. The maximum daily dose was 90 mg. The placebo infusion (0.9% NaCl) was started with a bolus dose of 17 ml in 30 min and continued with a constant rate of 2 ml kg -1 / 24 h for 48 h.
The infusions were given via an infusion pump (Terufusion Syringe Pump Model STC521; Terumo Corporation, Tokyo, Japan). All patients were allowed supplementary doses of morphine 2 mg ml -1 i.v. from a patient-controlled analgesia (PCA) device (Graseby Medical; Graseby Medical Ltd, Colonial Way, Watford, Herts, UK). The PCA device was programmed to provide a bolus dose of 30 µg kg -1 . The lockout time was 5-10 min until the first postoperative morning and thereafter 10-12 min. All patients stayed in the recovery room over the first postoperative night.
Patients were interviewed by an investigator who was blinded to the study infusion. The interview was performed when the patient arrived in the post-anaesthetic care unit and then every 60 min for 6 h. On the first postoperative day, patients were interviewed at 08:00 and 18:00, and on the second postoperative day at 08:00. Patients were asked about the intensity of wound pain at rest, when moving and when coughing, using a 50-cm visual analogue scale (VAS) 10 and a verbal rating scale (VRS: noneϭ0; mildϭ1; moderateϭ2; severeϭ3).
On the first and second postoperative days, patients were evaluated for adverse events (drowsiness, confusion, nausea, vomiting, itching, abdominal pain, dizziness, hallucinations, difficulties with breathing or allergic reactions). At the same time they rated their performance status (sleeping, mobility, drinking, eating and bowel function) using a scale of: absent 222 (0), moderately impaired (1), slightly impaired (2) or normal (3).
Urine output was measured until the second postoperative morning. If there was no spontaneous urine output, the bladder was catheterized on the first postoperative morning and, when needed, on the first postoperative evening. Crystalloids were infused until the first postoperative morning at 40 ml kg -1 via an infusion pump. Blood loss during operation and through the drainage after operation was measured. Blood loss less than 500 ml was replaced with 6% hydroxyethyl starch.
Blood haemoglobin concentration, packed red blood cell volume and serum creatinine concentration were measured before operation, 1 h after operation and on the first and second postoperative days. Arterial blood samples were obtained into silicon tubes for assay of plasma concentrations of diclofenac and ketorolac before and after the 30-min bolus infusion, and 30 min, 2, 6, 10, 16, 24 and 48 h after the start of continuous infusion.
Platelet count and IVY bleeding time (Simplate-II; General Diagnostics, Warner-Lambert Co., Morris Plains, NJ, USA) were performed by the same person before operation and 2 and 24 h after the start of infusion.
The platelet adhesion test (Adeplat S; Platelet Adhesion Test Set, Semmelweis Srl, div. Mascia Brunelli, Milano, Italy) was performed immediately before the start of infusion and 2 and 24 h later. Platelet adhesiveness was measured using an in vitro technique which involves the passage of a certain amount of native blood through a set of glass micro-beads. The rate of blood flow through the column was kept constant by an infusion pump (Adeplat Pump System). All variables which influence the retention of platelet by the glass were standardized. 11 Also, thromboelastography (TEG) 11 12 (Thrombelastograph D; Hellige GMBH, Freiburg im Breisgau, Germany) was performed immediately before the start of infusion and 2 and 24 h later. TEG tracings were analysed by measuring reaction time (r, min), coagulation time (k/rϩk, min) and maximum amplitude (MA, mm).
Plasma concentrations of diclofenac were measured by high-pressure liquid chromatography using electrochemical detection. 13 Flufenamic acid was used as internal standard. Samples were chromatographed in a C-18 inverse phase column. The limit of quantitation in the plasma diclofenac analysis was 0.03 mg litre -1 . The coefficient of variation for inter-assay determinations was 1.8% (nϭ7) at a concentration of 0.13 mg litre -1 , 5.43% (nϭ7) at a concentration of 1.3 mg litre -1 and 1.44% (nϭ7) at a concentration of 5.4 mg litre -1 , respectively.
Plasma concentrations of ketorolac were measured by high-pressure liquid chromatography using electrochemical detection. 14 15 Naproxen was used as internal standard. Samples were chromatographed in a C-18 inverse phase column. The limit of quantitation in the plasma ketorolac analysis was 0.05 mg litre -1 . The coefficient of variation for inter-assay determinations was 3.5% (nϭ7) at a concen-tration of 0.08 mg litre -1 , 1.9% (nϭ7) at a concentration of 0.8 mg litre -1 and 4.1% (nϭ7) at a concentration of 4.0 mg litre -1 , respectively. FEV 1 and forced vital capacity (FVC) were measured using a pocket spirometer (Micro Spirometer; Micro Medical Limited, Rochester, Kent, UK) 1 day before operation, 2, 4 and 6 h after operation, at 08:00 and 18:00 on the first postoperative day and at 08:00 on the second postoperative day. Patients breathed 35% oxygen via a Venturi mask at least until 6 h after surgery. Arterial bloodgas analysis was performed before and during surgery and every hour after operation until 6 h and on the first and second postoperative mornings. Oxygen saturation was monitored continuously by pulse oximetry (Sp O 2 ) using a finger probe until the first postoperative morning, on the first postoperative day at 18:00 and on the second postoperative day at 08:00. A chest x-ray was obtained 1 h after operation and on the first postoperative morning.
Statistical analysis
The Kruskal-Wallis test was used for comparison of patient characteristics between groups. A factorial analysis of variance was used for statistical analysis of morphine consumption after logarithmic transformation of the data followed by t test at individual times when needed. A twoway analysis of variance for repeated measures and Scheffé's method for testing all contrasts were used for statistical analysis of verbal rating scales for pain intensity (VRS pi ), visual analogue scales (VAS pi ), Pa O 2 /FI O 2 , Pa CO 2 , IVY bleeding times and platelet counts. Urine output, plasma creatinine concentration, platelet adhesion test values and blood loss were analysed using the Kruskal-Wallis test. The incidence of adverse events was compared using the chi-square test. PϽ0.05 was considered statistically significant. Mean (SEM) are presented. Calculations were performed using StatView 4.0 for Macintosh.
Results
All 30 patients completed the study; they were comparable in patient characteristics, surgery and anaesthesia (Table 1) . 
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Cumulative consumption of morphine was significantly less in the diclofenac and ketorolac groups compared with the placebo group from 16 to 44 h after surgery (PϽ0.05). Mean cumulative morphine consumption during the first 20 h was 57.4 (10.7) mg in the placebo group, 21.0 (4.0) mg in the diclofenac group and 31.6 (32.4) mg in the ketorolac group. During the second 24-h study period it was 35.9 (12.4) mg in the placebo group, 15.3 (5.4) mg in the diclofenac group and 13.3 (5.0) mg in the ketorolac group (Fig. 1) . The 95% confidence intervals for cumulative morphine consumption are presented in Table 2 .
There were no significant differences between groups for VAS pi (Fig. 2) or VRS pi values. The groups were also comparable for changes in FVC and FEV 1 (Fig. 3 ). There were no significant differences in Pa O 2 or Pa CO 2 values between groups (Table 3) .
Values for the platelet adhesion test, IVY bleeding time, platelet count and thromboelastography variables were comparable in the three groups before operation. There were no significant differences in the platelet adhesion test, IVY bleeding time and thromboelastography variables either between or within groups at any time ( Table 4) . 
Fig 2
Visual analogue scales for pain intensity (VAS), presented as percent difference from the maximum value on a 50-cm visual analogue scale, in the placebo, diclofenac and ketorolac groups, at rest and on coughing (mean (SEM)). There were no significant differences between groups. SEM is presented in one direction only. There were no significant differences between groups in creatinine concentration, urine output during the first and second postoperative days or in the amounts of crystalloids infused (Table 5) . Adverse events were comparable in the three groups.
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Individual plasma concentration curves for diclofenac and ketorolac are presented in Figure 4 . Inter-individual variation in the time-concentration curves was to some extent greater in the ketorolac than in the diclofenac group.
Discussion
We found that patients experienced moderate or even severe pain immediately after thoracoscopic surgery, even though it is considered a less traumatic procedure than conventional thoracotomy. 2 Surprisingly, mean cumulative consumption of morphine during the first postoperative day was only 17% less in the placebo group than that after thoracotomy in a similar study design. 4 In the diclofenac group, consumption of morphine was 30% less compared with that consumed after thoracotomy. The difference between these studies could have been greater if patients in the earlier study had not received intercostal blocks with 0.5% bupivacaine. 4 Previously, Kirby and colleagues 16 reported more postoperative complications in the thoracotomy group compared with VATS but no difference between groups in postoperative pain. In our study, all operations were minor thoracic procedures (biopsies of the lung or pleura, sympathectomies or extirpations of small benign tumours).
Diclofenac has been shown previously to have a significant morphine sparing effect after thoracotomy. 4 17 Diclofenac, given as a continuous i.v. infusion of 2 mg kg -1 / 24 h for 2 days, reduced postoperative i.v. PCA morphine consumption by more than 60%, with a significant reduction in VAS pi pain ratings also. 4 Ketorolac has been shown to be effective in postthoracotomy pain also. 5 18 19 Diclofenac and ketorolac have been shown to be equally effective in reducing pain and opioid requirements after laparoscopy 20 and after maxillofacial surgery. 21 No significant difference in the morphine sparing effect of these two NSAID was demonstrated in our study. Power analysis showed that with an α-error of 0.05 and β-error of 0.20, 10 patients were required per group to detect a 75 mg difference in consumption of morphine between the diclofenac and placebo groups during a 48-h period. For this calculation, we used an SD of 58.6 (placebo) and mean difference between groups of 93 mg in 48 h. This sample size calculation was based on our earlier study using a similar study design. 4 In this present study, however, the difference between these two treatments (placebo and diclofenac) was 57 mg over 44 h. One explanation could be that the operation type caused even less pain than expected. The 95% confidence intervals for cumulative morphine consumption indicated that there may have been a difference between the diclofenac and ketorolac groups which we could not detect because of the small number of patients in each group. However, both NSAID had a significant morphine sparing effect after thoracoscopic surgery.
The fact that neither diclofenac nor ketorolac had effects on haemostasis compared with the placebo group is in agreement with previous studies. 4 22 It should be noted, however, that our patients did not receive prophylaxis for deep venous thrombosis, which could potentially increase the risk of haemostatic complications of NSAID. 23 Acute renal failure is a potential complication associated with the use of NSAID during and after surgery, especially in patients with pre-existing renal disease or those with hypovolaemia and receiving loop diuretics. Patients undergoing thoracic operations are often i.v. fluid restricted to prevent postoperative pulmonary complications. Smaller volumes of i.v. crystalloids than generally recommended for surgical patients after operation, combined with a possible stress response, can manifest as reduced urine output in patients receiving NSAID for postoperative pain. In our study, i.v. crystalloid fluid volumes were comparable with those generally recommended for surgical patients and there were no differences between groups in urine output or serum creatinine values during the first two postoperative days.
In this study, patients received continuous infusion of diclofenac or ketorolac for 48 h. Plasma concentrations of diclofenac and ketorolac were also measured for 48 h to ensure that steady state was reached as both drugs have 225 different elimination half-lives (diclofenac 1-2 h vs ketorolac 5 h). 24 25 Inter-individual variability in plasma concentrations of ketorolac was greater compared with that of diclofenac. Steady state may be considered to be reached in 3.3 half-lives, which is approximately 16.5 h for ketorolac. The time to reach the plateau stage should have been shorter than 16.5 h in this study because patients received a bolus
Fig 4
Individual plasma concentration curves for diclofenac and ketorolac concentrations. In one patient in the diclofenac group, the 24 h plasma concentration was below the quantitation limit because the infusion was disconnected for 2 h.
dose of ketorolac 10 mg. Mean C P max after an i.v. bolus dose of ketorolac 10 mg was 2.39 (SD 1.30) µg ml -1 in a single dose study in healthy volunteers. Mean plasma concentration of ketorolac after an i.v. bolus dose of 10 mg decreased from approximately 1 to 0.1 µg ml -1 in 10 h. 26 Mean plasma concentration of diclofenac after an i.v. bolus dose of 50 mg decreased from approximately 8 to 0.5 µg ml -1 in 1 h. 24 In our study, concentrations of ketorolac and diclofenac were similar to those reported previously. 24 26 Plasma concentration-time curves of diclofenac and ketorolac showed that all patients had measurable concentrations of NSAID in blood. However, in common with other NSAID, clinical efficacy is probably not related directly to plasma concentrations of diclofenac or ketorolac. Both i.v. diclofenac and ketorolac were not associated with problems with haemostasis or renal function. Both infusions significantly reduced morphine consumption with no effect on outcome in terms of hospital stay or respiratory, renal or haematological function. The fact that patients experienced moderate to severe pain during the first hour after thoracoscopic surgery indicates that these patients could benefit from intercostal nerve block in addition to i.v. NSAID and opioids.
